Tantavisut Saran, Ho Kok Yuen, Arandia Edsel F, Cheng Sze Chung, Eiamtanasate Sarasate, Jarayabhand Rahat, Kokseng Raymond Alvin J, Paco Jesse Jane L, Raju Gopinathan, Suwanpramote Prakrit, Thepsoparn Marvin, Nagrale Dinesh
Orthopaedics, Chulalongkorn University, Bangkok, THA.
Pain Management & Anaesthesiology, The Pain Clinic, Mount Alvernia Medical Centre, Singapore, SGP.
Cureus. 2023 Jun 29;15(6):e41156. doi: 10.7759/cureus.41156. eCollection 2023 Jun.
Multimodal analgesia is key in the effective management of acute pain. Previous clinical trials have demonstrated good results with the use of a fixed-dose combination (FDC) of tramadol 75 mg and dexketoprofen 25 mg (TRAM/DKP) in acute pain management. However, there is a dearth of real-world evidence on the efficacy and safety of this combination in the management of acute non-surgical pain, especially among Asian patients. The case series reported herein investigates the real-world experiences of physicians and Asian patients with the use of TRAM/DKP FDC in the management of acute non-surgical pain.
Data were collected retrospectively on 11 Asian patients across multiple hospitals who had received a short course of TRAM/DKP FDC for acute non-surgical orthopaedic and non-orthopaedic pain. Data on baseline characteristics, medical history, treatment regimen, clinical outcomes, and patient satisfaction were compiled and shared at a peer-to-peer expert meeting in October 2022.
All patients experienced a reduction in pain intensity and were very satisfied with pain management, with a mean satisfaction score of 4.3/5. Five patients (range: 63-74 years) experienced mild adverse events, including nausea, vomiting, and dizziness, which resolved with no need for additional treatment in the majority of cases. No serious adverse events were recorded.
Asian patients with acute non-surgical orthopaedic and non-orthopaedic pain achieved good pain control with TRAM/DKP FDC. The regimen was well tolerated, and patients reported high levels of satisfaction with the outcomes, indicating that TRAM/DKP FDC is an effective choice for the control of acute non-surgical pain in Asian patients.
多模式镇痛是有效管理急性疼痛的关键。先前的临床试验表明，在急性疼痛管理中使用曲马多75毫克和右酮洛芬25毫克的固定剂量组合（TRAM/DKP）可取得良好效果。然而，关于该组合在急性非手术疼痛管理中的疗效和安全性，尤其是在亚洲患者中的真实世界证据匮乏。本文报道的病例系列研究了医生和亚洲患者在使用TRAM/DKP固定剂量组合管理急性非手术疼痛方面的真实世界经验。
回顾性收集了多家医院11例亚洲患者的数据，这些患者接受了短期TRAM/DKP固定剂量组合治疗急性非手术性骨科和非骨科疼痛。收集了关于基线特征、病史、治疗方案、临床结果和患者满意度的数据，并在2022年10月的同行专家会议上进行了汇总和分享。
所有患者的疼痛强度均有所降低，对疼痛管理非常满意，平均满意度评分为4.3/5。5例患者（年龄范围：63 - 74岁）出现轻度不良事件，包括恶心、呕吐和头晕，大多数情况下无需额外治疗即可缓解。未记录到严重不良事件。
患有急性非手术性骨科和非骨科疼痛的亚洲患者使用TRAM/DKP固定剂量组合可实现良好的疼痛控制。该治疗方案耐受性良好，患者对治疗结果满意度较高，表明TRAM/DKP固定剂量组合是控制亚洲患者急性非手术疼痛的有效选择。
